Emergent BioSolutions Enters $34.5M Vaccine Agreement with Substipharm
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy EBS?
Source: seekingalpha
- Vaccine Production Agreement: Emergent BioSolutions has entered into a $34.5 million agreement with Substipharm Biologics, focusing on drug substance production for the IMOJEV Japanese Encephalitis vaccine, marking a strategic expansion in the vaccine sector.
- Exclusive Distribution Rights: Under the agreement, Emergent will serve as the exclusive distributor to the U.S. government pending FDA approval, ensuring its critical role and market access in public health.
- Production Capacity Increase: This agreement will drive Emergent to scale up production at its Canton, Massachusetts facility and plans to hire additional staff to meet the growing vaccine demand.
- Regulatory Support: The collaboration will support Emergent's regulatory submission efforts for U.S. vaccine approval, further solidifying its position in the biopharmaceutical industry and driving future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EBS
Wall Street analysts forecast EBS stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.500
Low
15.00
Averages
15.00
High
15.00
Current: 9.500
Low
15.00
Averages
15.00
High
15.00
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hantavirus Outbreak Triggers Surge in Pharma Stocks
- Pharma Stock Surge: Following the WHO's May 2 warning about the hantavirus outbreak, Moderna's stock rose 7% in premarket trading, indicating market confidence in its ability to address emerging infectious diseases.
- Research Collaboration: Moderna is conducting preclinical research on hantaviruses in collaboration with the US Army Medical Research Institute, although Evercore ISI believes this will not lead to significant revenue opportunities, it highlights the agility of its mRNA platform.
- Other Companies' Performance: Inovio Pharmaceuticals jumped 11% in early trading, while Novavax rose 5%, reflecting positive market sentiment towards vaccine development firms, despite limited overall market opportunities.
- Epidemic Control Status: President Trump stated that the outbreak on the cruise ship is under control, with the WHO reporting 8 confirmed cases and 3 deaths, assessing the public health risk as low, indicating the situation is manageable.
See More
Hantavirus Outbreak Drives Pharmaceutical Stocks Up
- Pharmaceutical Stocks Surge: Following the hantavirus outbreak, pharmaceutical stocks such as Moderna, Inovio, Novavax, and Emergent Biosolutions saw significant premarket gains, with Moderna rising 7%, Inovio up 13%, and Emergent and Novavax increasing by 4% and 3% respectively, indicating heightened investor interest in outbreak-related companies.
- Market Reaction Analysis: Evercore ISI analysts noted that despite the stock increases, the revenue opportunity from hantavirus is limited, suggesting that the current price fluctuations are primarily sentiment-driven rather than based on fundamental changes, and highlighting that Moderna's mRNA platform agility is already well understood by the market.
- Epidemic Background: The World Health Organization confirmed the hantavirus outbreak on May 2, stating that the virus is transmitted by rodents; although there have been 8 reported cases and 3 deaths, the public health risk is assessed as low, indicating that the severity of the outbreak is limited.
- Government Response Measures: U.S. President Trump stated that the outbreak is under control and promised a report on the virus soon, emphasizing the government's proactive stance in managing the situation, which may further influence market sentiment and investor confidence.
See More
Trump Promises Full Report on Hantavirus Outbreak
- Outbreak Overview: The hantavirus outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths and six confirmed infections among 150 passengers, prompting global attention, with Trump promising a detailed report on Friday, indicating the government's seriousness about the situation.
- Vaccine Development Update: Moderna's partnership with Korea University to develop an mRNA hantavirus vaccine has gained attention, receiving a $176 million government award in 2024, highlighting its critical role in pandemic response and potential to accelerate vaccine development timelines.
- Market Reaction: Vaccine manufacturers and biodefense companies saw stock rallies on Friday night, with Emergent BioSolutions up 3%, Inovio and Novavax each gaining 2%, and Moderna rising 1%, reflecting investor optimism regarding vaccine development amid the outbreak.
- Investor Sentiment: On Stocktwits, retail sentiment for Inovio and Novavax was extremely bullish, while Moderna showed positive sentiment, indicating high market interest in hantavirus-related companies, with Moderna's stock surging 102% over the past year.
See More
Emergent BioSolutions Q1 2026 Earnings Call Insights
- Financial Performance: Emergent BioSolutions reported Q1 2026 revenue of $156 million and adjusted EBITDA of $36 million, representing a 23% margin, indicating stable performance despite market challenges.
- International Market Growth: International markets now account for 37% of total MCM revenue, demonstrating significant progress in global expansion, which is expected to further drive revenue growth and market share enhancement.
- Strategic Partnerships: New strategic partnerships with Substipharm Biologics and SAB Biotherapeutics will restart manufacturing at the Canton facility to support the Japanese encephalitis vaccine, showcasing the company's strategic positioning in vaccine production capabilities.
- Future Outlook: The company maintains full-year revenue guidance of $720 million to $760 million and expects Q2 revenue between $170 million and $185 million, reflecting management's confidence in future performance despite pricing pressures.
See More
Emergent BioSolutions' ACAM2000 Vaccine Approved for Mpox Prevention in Singapore
- Vaccine Indication Expansion: Emergent BioSolutions announced that its ACAM2000 vaccine has received approval from Singapore's Health Sciences Authority to expand its indication for the prevention of mpox disease in high-risk adults, showcasing the company's proactive role in public health.
- Clinical Data Support: The approval is backed by existing human safety data and a well-controlled animal study demonstrating ACAM2000's effectiveness in protecting against mpox virus exposure, which enhances market confidence in the vaccine.
- Vaccination Administration: ACAM2000 is a single-dose vaccine administered through a bifurcated needle that pricks the skin multiple times in the upper arm, ensuring effective inoculation while simplifying the vaccination process and improving accessibility.
- Positive Market Reaction: Following the approval from Singapore's HSA, Emergent BioSolutions' stock rose by 1.94% in pre-market trading on the New York Stock Exchange, reaching $8.15 per share, reflecting market optimism regarding the vaccine's prospects.
See More
Emergent Biosolutions to Announce Q1 Earnings on April 30
- Earnings Announcement: Emergent Biosolutions (EBS) is set to release its Q1 2023 earnings report on April 30 after market close, with consensus EPS estimate at -$0.38 and revenue forecast at $145 million, reflecting a 34.7% year-over-year decline.
- Historical Performance: Over the past two years, EBS has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a mixed financial performance trend that may affect investor sentiment.
- Manufacturing Deal: EBS has signed a multi-year manufacturing agreement with SAB Biotherapeutics valued at approximately $50 million, aimed at enhancing its production capabilities and expanding market presence.
- Vaccine Production Agreement: The company also secured a $34.5 million vaccine manufacturing and distribution deal, further solidifying its position in the biopharmaceutical sector.
See More
Hantavirus Outbreak Triggers Surge in Pharma Stocks
- Pharma Stock Surge: Following the WHO's May 2 warning about the hantavirus outbreak, Moderna's stock rose 7% in premarket trading, indicating market confidence in its ability to address emerging infectious diseases.
- Research Collaboration: Moderna is conducting preclinical research on hantaviruses in collaboration with the US Army Medical Research Institute, although Evercore ISI believes this will not lead to significant revenue opportunities, it highlights the agility of its mRNA platform.
- Other Companies' Performance: Inovio Pharmaceuticals jumped 11% in early trading, while Novavax rose 5%, reflecting positive market sentiment towards vaccine development firms, despite limited overall market opportunities.
- Epidemic Control Status: President Trump stated that the outbreak on the cruise ship is under control, with the WHO reporting 8 confirmed cases and 3 deaths, assessing the public health risk as low, indicating the situation is manageable.
See More
Hantavirus Outbreak Drives Pharmaceutical Stocks Up
- Pharmaceutical Stocks Surge: Following the hantavirus outbreak, pharmaceutical stocks such as Moderna, Inovio, Novavax, and Emergent Biosolutions saw significant premarket gains, with Moderna rising 7%, Inovio up 13%, and Emergent and Novavax increasing by 4% and 3% respectively, indicating heightened investor interest in outbreak-related companies.
- Market Reaction Analysis: Evercore ISI analysts noted that despite the stock increases, the revenue opportunity from hantavirus is limited, suggesting that the current price fluctuations are primarily sentiment-driven rather than based on fundamental changes, and highlighting that Moderna's mRNA platform agility is already well understood by the market.
- Epidemic Background: The World Health Organization confirmed the hantavirus outbreak on May 2, stating that the virus is transmitted by rodents; although there have been 8 reported cases and 3 deaths, the public health risk is assessed as low, indicating that the severity of the outbreak is limited.
- Government Response Measures: U.S. President Trump stated that the outbreak is under control and promised a report on the virus soon, emphasizing the government's proactive stance in managing the situation, which may further influence market sentiment and investor confidence.
See More
Trump Promises Full Report on Hantavirus Outbreak
- Outbreak Overview: The hantavirus outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths and six confirmed infections among 150 passengers, prompting global attention, with Trump promising a detailed report on Friday, indicating the government's seriousness about the situation.
- Vaccine Development Update: Moderna's partnership with Korea University to develop an mRNA hantavirus vaccine has gained attention, receiving a $176 million government award in 2024, highlighting its critical role in pandemic response and potential to accelerate vaccine development timelines.
- Market Reaction: Vaccine manufacturers and biodefense companies saw stock rallies on Friday night, with Emergent BioSolutions up 3%, Inovio and Novavax each gaining 2%, and Moderna rising 1%, reflecting investor optimism regarding vaccine development amid the outbreak.
- Investor Sentiment: On Stocktwits, retail sentiment for Inovio and Novavax was extremely bullish, while Moderna showed positive sentiment, indicating high market interest in hantavirus-related companies, with Moderna's stock surging 102% over the past year.
See More
Emergent BioSolutions Q1 2026 Earnings Call Insights
- Financial Performance: Emergent BioSolutions reported Q1 2026 revenue of $156 million and adjusted EBITDA of $36 million, representing a 23% margin, indicating stable performance despite market challenges.
- International Market Growth: International markets now account for 37% of total MCM revenue, demonstrating significant progress in global expansion, which is expected to further drive revenue growth and market share enhancement.
- Strategic Partnerships: New strategic partnerships with Substipharm Biologics and SAB Biotherapeutics will restart manufacturing at the Canton facility to support the Japanese encephalitis vaccine, showcasing the company's strategic positioning in vaccine production capabilities.
- Future Outlook: The company maintains full-year revenue guidance of $720 million to $760 million and expects Q2 revenue between $170 million and $185 million, reflecting management's confidence in future performance despite pricing pressures.
See More
Emergent BioSolutions' ACAM2000 Vaccine Approved for Mpox Prevention in Singapore
- Vaccine Indication Expansion: Emergent BioSolutions announced that its ACAM2000 vaccine has received approval from Singapore's Health Sciences Authority to expand its indication for the prevention of mpox disease in high-risk adults, showcasing the company's proactive role in public health.
- Clinical Data Support: The approval is backed by existing human safety data and a well-controlled animal study demonstrating ACAM2000's effectiveness in protecting against mpox virus exposure, which enhances market confidence in the vaccine.
- Vaccination Administration: ACAM2000 is a single-dose vaccine administered through a bifurcated needle that pricks the skin multiple times in the upper arm, ensuring effective inoculation while simplifying the vaccination process and improving accessibility.
- Positive Market Reaction: Following the approval from Singapore's HSA, Emergent BioSolutions' stock rose by 1.94% in pre-market trading on the New York Stock Exchange, reaching $8.15 per share, reflecting market optimism regarding the vaccine's prospects.
See More
Emergent Biosolutions to Announce Q1 Earnings on April 30
- Earnings Announcement: Emergent Biosolutions (EBS) is set to release its Q1 2023 earnings report on April 30 after market close, with consensus EPS estimate at -$0.38 and revenue forecast at $145 million, reflecting a 34.7% year-over-year decline.
- Historical Performance: Over the past two years, EBS has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a mixed financial performance trend that may affect investor sentiment.
- Manufacturing Deal: EBS has signed a multi-year manufacturing agreement with SAB Biotherapeutics valued at approximately $50 million, aimed at enhancing its production capabilities and expanding market presence.
- Vaccine Production Agreement: The company also secured a $34.5 million vaccine manufacturing and distribution deal, further solidifying its position in the biopharmaceutical sector.
See More
